Revive Therapeutics Ltd (RVVTF)

[rickstereo3333]

The avip trial targeted critically ill hospitalized patients and FAILED, as you clearly presented, to meet the primary ep criteria, while the secondary ep did not prove to be worthwhile of acceptance.

No amount of spin is going to change those facts.

You also seem very confused since buccy is for a totally different cohort of patients, ie those with mild-mod symptoms which obviously represents a vastly wider population.

This group does not overlap with the relief cohort in any significant way, if at all, thus making your continued comparisons of the two situations even sillier.

Theres a huge difference between ""being alive and free of respiratory failure for 60 days"" and achieving ""improvement in at least two COVID-19 related clinical symptoms on or before day 14"" .

Clearer now!?!?!